T cell activation in the organ recipient is what typically causes organ rejection, and they become fully activated when they make physical contact with a specialized type of cell, the dendritic cell.
The study, led by researchers from the University of Pittsburgh School of Medicine, found dendritic cells help drive rejection of transplanted organs.
“Our study indicates that eliminating transplant-infiltrating dendritic cells reduces proliferation and survival of T cells within the graft with the consequent prolongation of transplant survival,” said Adrian Morelli, MD, PhD, associate professor of surgery and immunology at the Thomas E. Starzl Transplant Institute at the University of Pittsburgh and co-author of the study.
“The next step would be to devise methods to specifically target dendritic cells within transplanted organs,” said Fadi Lakkis, MD, a professor of immunology and surgery at the University of Pittsburgh, director of the Starzl Transplant Institute and study co-author. “Such methods carry promise of preventing or interrupting rejection without compromising the patient’s overall immune defenses.”
More articles on organ transplants:
Nation’s transplant system looks for new ways to distribute livers more fairly
Hospitals disposing of organs, refusing transplants to maintain federal performance ratings
Should physicians bend rules to get patients new hearts amid donor shortages?
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
